1981
DOI: 10.1159/000316304
|View full text |Cite
|
Sign up to set email alerts
|

Rifampicin in Free Combination with Other Antimicrobial Drugs in Non-Tb Infections (Part 2 of 2)

Abstract: A review of the published literature has allowed the identification of a number of non-tubercular indications where rifampicin (trade mark Ciba-Geigy: Rimactane>) has been successfully used in combination with other chemotherapeutic agents. The cases reviewed with regard to effectiveness sum 562. The most frequently combined drugs were aminoglycosides (mainly gentamicin), cotrimoxazole, colistine, vancomycin and fusidic acid, these two latter in cases due to Staphylococcus spp. The main indications … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
2
0

Year Published

1994
1994
2019
2019

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 2 publications
1
2
0
Order By: Relevance
“…Such reactions also were not observed, and they were previously ascribed more to the intermittency of dosing than the higher rifampin dose used (10,19). The good tolerability of 900 and 1,200 mg of rifampin is in agreement with that when such doses are used to treat other diseases, such as brucellosis, leishmaniasis, and bone and joint infections (20)(21)(22), although treatment of these diseases requires less toxic drugs to be coadministered with rifampin.…”
Section: Discussionsupporting
confidence: 54%
“…Such reactions also were not observed, and they were previously ascribed more to the intermittency of dosing than the higher rifampin dose used (10,19). The good tolerability of 900 and 1,200 mg of rifampin is in agreement with that when such doses are used to treat other diseases, such as brucellosis, leishmaniasis, and bone and joint infections (20)(21)(22), although treatment of these diseases requires less toxic drugs to be coadministered with rifampin.…”
Section: Discussionsupporting
confidence: 54%
“…PK-PD analysis revealed that higher exposures to rifampicin were the intermediary link to the decreased time to culture conversion and showed that this effect of rifampicin did not plateau at the 35 mg/kg dose [70]. Higher doses of rifampicin up to 20 mg/kg have also been studied and were safe and tolerable for other diseases such as brucellosis [71], leishmaniasis [72], and other indications [73].…”
Section: Rifampicinmentioning
confidence: 99%
“…The MRSA strain of our patient was sensitive to old agents such as RFP and SMZ/TMP. Most staphylococci have high susceptibility to RFP, but RFP has been suggested as adjunctive therapy in patients who do not respond adequately to conventional antimicrobial therapy [4,7], because resistance develops rapidly when this agent is used alone. SMZ/TMP was reported to be a useful alternative to VCM for treatment of MRSA infections in IDUs, but clinical experience with this agent for MRSA IE is limited [4].…”
Section: Discussionmentioning
confidence: 99%